02.02. Área de Salud II Cartagena

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study

2026-09-01T00:00:00Z

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study Bellido, Virginia; Cebrián-Cuenca, Ana-María; Morales, Cristobal; de-las-Hazas, Alberto-S; Soto-González, Alfonso; Morer-Linan, Carla; Borrachero-Guijarro, José-Miguel; Cuatrecases, Gabriel; García, Elena-L; López-Fernández, Judith; Lozano-García, Silvia; Bayon, Alvaro-M; Nino-Azcarate, Cristina-M; Laclaustra, Oscar; Fuentealba, Paulina INTRODUCTION: Hypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain. METHODS: GPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ? 6 months in primary care. Participants underwent 14 days of blinded CGM (FreeStyle Libre(®) Pro iQ(®)). The primary objective of the present study was to estimate the proportion of patients with T2DM treated with Gla-100 whose TBR (glucose < 70 mg/dL) exceeded the internationally recommended threshold of 4%. Secondary endpoints included time in range (TIR), time above range (TAR), episodes of clinically significant hypoglycemia (< 54 mg/dL), cognitive function (MMSE), and fear of hypoglycemia (EsHFS). RESULTS: Among 136 patients (mean age 69 years), 16.9% had TBR > 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (< 54 mg/dL > 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent > 25% of the day between 181-250 mg/dL, and 28.7% spent time > 250 mg/dL. Only 55.9% achieved TIR ? 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE < 23) was associated with longer hypoglycemia duration. CONCLUSIONS: Blinded CGM revealed a relevant burden of unrecognized hypoglycemia-particularly nocturnal-as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.

Stability Study of a Frozen Oseltamivir 15 mg/mL Oral Solution in Amber Glass Bottles

2026-09-08T00:00:00Z

Stability Study of a Frozen Oseltamivir 15 mg/mL Oral Solution in Amber Glass Bottles Ruiz-Ramírez, Juan-Carlos; Gómiz-Sáez, Adrián; Martínez-Madrid, María-Encarnación; Viney, Alice-Charlotte; Alonso-Herreros, José-María; Almela-Rojo, Pilar

Stability Study of Meropenem 50 mg/mL Eye Drops in Polypropylene Dropper Bottles

2026-08-07T00:00:00Z

Stability Study of Meropenem 50 mg/mL Eye Drops in Polypropylene Dropper Bottles Ruiz-Ramírez, Juan-Carlos; Martínez-Madrid, María-Encarnación; Gómiz-Sáez, Adrián; Viney, Alice-Charlotte; Alonso-Herreros, José-María; Almela-Rojo, Pilar

Fascin-Centred Invasive Competence in Eutopic Endometrium: A Hypothesis-Driven Narrative Review of Endometriosis Pathogenesis and Non-Surgical Biomarker Potential

2026-08-13T00:00:00Z

Fascin-Centred Invasive Competence in Eutopic Endometrium: A Hypothesis-Driven Narrative Review of Endometriosis Pathogenesis and Non-Surgical Biomarker Potential Marín-Sánchez, María-del-Pilar; Ortega-Suárez, Daimaris; López-Soto, Álvaro; Kozak-Hensor, Irina; Benito-Villena, Rebeca; Vives-Ramírez, Marina; Postigo-Corrales, Fátima; Isaac-Montero, Alejandra; Conesa-Zamora, Pablo; Luengo-Gil, Ginés Endometriosis is a chronic, oestrogen-responsive inflammatory disease characterised by endometrial-like tissue outside the uterine cavity. Because retrograde menstruation is common, lesion establishment probably requires cellular competence and a permissive ectopic microenvironment. This hypothesis-driven narrative review evaluates fascin (FSCN1) as a candidate cytoskeletal effector and considers antecedent eutopic priming versus induction after ectopic adhesion. Functional evidence was integrated with a targeted public-data screen. Donor-level reanalysis of GSE179640 found no conclusive overall eutopic case-control difference and predominantly non-epithelial expression. Exploratory analysis of GSE203191 suggested higher FSCN1 expression within a HSPA6+ stromal subcluster in diagnosed cases, without a comparable epithelial signal or detectable increase in subcluster abundance. This small post hoc analysis remains hypothesis-generating. FSCN1 was absent from the published HECA stromal/macrophage differential-expression lists and was not prioritised by the 2023 endometriosis GWAS. The current evidence therefore argues against uniform epithelial or whole-eutopic overexpression but permits a lineage-restricted stromal state. Fascin participates in autophagy- and miR-145-sensitive invasion networks, although these pathways are pleiotropic. Validation requires cycle- and lineage-resolved tissue mapping, compositional controls, matched lesions, and direct FSCN1 perturbation. Fascin should currently be regarded as a candidate multi-marker component and preclinical target, not a validated biomarker or systemic therapeutic target.